Merck Arcoxia Acute Gout Trials Use Appropriate Comparator, Cmte. Says
Executive Summary
Merck's comparison of Arcoxia to indomethacin in trials of acute gout is appropriate even though there is little formal data on indomethacin's efficacy, FDA's Arthritis Advisory Committee said
You may also be interested in...
“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs
The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
Oxyprim Gout Therapy To Be Limited To Allopurinol Failures, Cardiome Says
Cardiome's risk management plan for the chronic gout therapy Oxyprim would require proof of patient failure on standard therapy before administration, Exec VP-Clinical Development Alan Moore, PhD, said June 2
Oxyprim Gout Therapy To Be Limited To Allopurinol Failures, Cardiome Says
Cardiome's risk management plan for the chronic gout therapy Oxyprim would require proof of patient failure on standard therapy before administration, Exec VP-Clinical Development Alan Moore, PhD, said June 2